Real-world evidence (RWE) published in Blood demonstrated the efficacy of CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in older patients. While median overall survival was similar between adults 65 and up and adults over 75, median event-free survival was better in the adults over 65 but younger than 75.
According to Jared Kaltwaser, “Eighty-three percent of patients who received CAR T-cell therapy received it in an inpatient setting, the authors said, and they stayed in the hospital for an average 21 days. The median total health care cost during the 90-day follow-up period was $352,572, the authors said.”
To read more, click here.
(Source: AJMC, June 27th, 2023)